Tong Ren Tang Technologies Co. Ltd. (TGRNF)
USD 0.69
(0.0%)
USD 0.69
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 6.77 Billion CNY | 13.04% |
| 2022 | 5.99 Billion CNY | 10.95% |
| 2021 | 5.4 Billion CNY | 17.21% |
| 2020 | 4.6 Billion CNY | 2.92% |
| 2019 | 4.47 Billion CNY | -11.53% |
| 2018 | 5.05 Billion CNY | 0.69% |
| 2017 | 5.02 Billion CNY | 7.71% |
| 2016 | 4.66 Billion CNY | 17.01% |
| 2015 | 3.98 Billion CNY | 19.33% |
| 2014 | 3.34 Billion CNY | 14.79% |
| 2013 | 2.91 Billion CNY | 18.95% |
| 2012 | 2.44 Billion CNY | 26.37% |
| 2011 | 1.93 Billion CNY | 22.64% |
| 2010 | 1.57 Billion CNY | 20.72% |
| 2009 | 1.3 Billion CNY | 7.96% |
| 2008 | 1.21 Billion CNY | 4.7% |
| 2007 | 1.15 Billion CNY | 11.82% |
| 2006 | 1.03 Billion CNY | -8.89% |
| 2005 | 1.13 Billion CNY | 15.5% |
| 2004 | 983.24 Million CNY | 13.67% |
| 2003 | 864.97 Million CNY | 30.49% |
| 2002 | 662.89 Million CNY | 33.28% |
| 2001 | 497.37 Million CNY | 46.85% |
| 2000 | 338.69 Million CNY | 9.94% |
| 1999 | 308.06 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 561.89 Million USD | 0.0% |
| 2023 FY | 6.77 Billion CNY | 13.04% |
| 2023 Q2 | 569.37 Million USD | 0.0% |
| 2023 Q4 | 391.02 Million USD | 0.0% |
| 2022 Q4 | 427.62 Million USD | 0.0% |
| 2022 Q2 | 463.77 Million USD | 0.0% |
| 2022 FY | 5.99 Billion CNY | 10.95% |
| 2021 Q2 | 427.4 Million USD | 0.0% |
| 2021 FY | 5.4 Billion CNY | 17.21% |
| 2021 Q4 | 408.85 Million USD | 0.0% |
| 2020 FY | 4.6 Billion CNY | 2.92% |
| 2020 Q4 | 349.26 Million USD | 0.0% |
| 2020 Q2 | 318.99 Million USD | 0.0% |
| 2019 Q2 | 366.12 Million USD | 0.0% |
| 2019 FY | 4.47 Billion CNY | -11.53% |
| 2019 Q4 | 286.03 Million USD | 0.0% |
| 2018 FY | 5.05 Billion CNY | 0.69% |
| 2017 FY | 5.02 Billion CNY | 7.71% |
| 2016 FY | 4.66 Billion CNY | 17.01% |
| 2015 FY | 3.98 Billion CNY | 19.33% |
| 2014 FY | 3.34 Billion CNY | 14.79% |
| 2013 FY | 2.91 Billion CNY | 18.95% |
| 2012 FY | 2.44 Billion CNY | 26.37% |
| 2011 FY | 1.93 Billion CNY | 22.64% |
| 2010 FY | 1.57 Billion CNY | 20.72% |
| 2009 FY | 1.3 Billion CNY | 7.96% |
| 2008 FY | 1.21 Billion CNY | 4.7% |
| 2007 FY | 1.15 Billion CNY | 11.82% |
| 2006 FY | 1.03 Billion CNY | -8.89% |
| 2005 FY | 1.13 Billion CNY | 15.5% |
| 2004 FY | 983.24 Million CNY | 13.67% |
| 2003 FY | 864.97 Million CNY | 30.49% |
| 2002 FY | 662.89 Million CNY | 33.28% |
| 2001 FY | 497.37 Million CNY | 46.85% |
| 2000 FY | 338.69 Million CNY | 9.94% |
| 1999 FY | 308.06 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AstraZeneca PLC | 46.91 Billion USD | 85.562% |
| Bristol-Myers Squibb Company PFD CONV 2 | 45 Billion USD | 84.95% |
| CSPC Pharmaceutical Group Limited | 31.45 Billion USD | 78.463% |
| Clarus Therapeutics Holdings, Inc. | 13.95 Million USD | -48430.938% |
| Novartis AG | 46.66 Billion USD | 85.483% |
| PT Kalbe Farma Tbk. | 1.97 Billion USD | -242.233% |